Table 3 The preclinical studies in CAR NKT cells
From: CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy
Target | Generation | Cancer | Expansion | Activation | Costimulator | Ref. |
|---|---|---|---|---|---|---|
GD2 | Second/third | Neuroblastoma | IL-2 | Feeder cell with α-GalCer | CD28/ 4-1BB/ both | [235] |
GD2 | Second/fourth | Neuroblastoma | IL-2,7,21 | Irritated auto NKT-negative cell with α-GalCer | CD28/ 4-1BB | [63] |
CD19 | Second | B-cell lymphoma | IL-2 | Irritated auto NKT-negative cell with α-GalCer | 4-1BB | [97] |
CD19 | Second | B-cell lymphoma | IL-2,7,21 | Irritated auto NKT-negative cell with α-GalCer | CD28/OX40-CD28 | [77] |
CD19 | Second/third | B-cell lymphoma | IL-2 and 15 | Irritated auto PBMC pulsed with CD38/28 | 4-1BB | [12] |
CSPG4 | Second | Melanoma | IL-2 | Anti CD3 antibody | CD28 | [236] |
CD38/BMCA | Second | Multiple myeloma | IL-2,7,15 | Irritated auto NKT-negative cell with α-GalCer | CD28/4-1BB | [237] |
CD19, CEA, or HER2 | Second | B-cell lymphoma | IL-2 | cytokine-induced killer cells (CIKZ) | CD28 | [98] |